Social Sentiment Ticker Powered by AI
Social Sentiment Ticker Powered by AI
Download App
Master the Markets with TradeZing PLUS’s AI Powered Tools
Learn More
Host your events on tradezing app
COMMUNITY AUDIO ROOMS
No available audio rooms
Upcoming Events
TradeZing
TradeZing
Bitcoins next massive move will shock investors!!! $BTC $BITI $BITO $HODL $IBIT $ARKB $BTCW $GBTC
Bitcoins next massive move will shock investors!!! $BTC $BITI $BITO $HODL $IBIT $ARKB $BTCW $GBTC
8 Day9 Hr31 Min30 Sec
YouTube
Get the TradeZing Newsletter
Supercharge
Your Money Making Potential
Watch your wealth rise with the power of AI research tools only with TradeZing PLUS!
Subscribe Now
EXCLUSIVE
Trade the Day
With Larry Benedict and Eric Shamilov
Trade together with legendary hedge fund manager Larry Benedict every morning before the bell
Everyday at 8:45 AM EST
What is Trade the Day?
Get ahead of the market curve each trading day with Larry Benedict, a distinguished Barron’s Top 100 hedge fund manager and the founder of the Opportunistic Trader ETF (WZRD). With his analyst, Eric Shamilov, Larry provides live, pre-market trading insights and strategic analysis, equipping you with the knowledge to make smart trading decisions.
Not a TradeZing PRO Member?
Subscribe now for exclusive advantages and benefits!
TZ PLUS Cash Back
Latest Feed
May 16, 2024
24 mins ago
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.
181491
News
May 16, 2024
24 mins ago
LED Lighting and EV Charging Solutions Provider Orion Previews FY 2024 Results in Anticipation of its Singular Research Webinar Presentation Wed. May 22 at 3pm ET
LED Lighting and EV Charging Solutions Provider Orion Previews FY 2024 Results Ahead of its Singular Research Webinar Presentation, Wed. 5/22 at 3pm ET.
181492
News
May 16, 2024
26 mins ago
4 Analysts Assess OncoCyte: What You Need To Know
Analysts’ ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 21.67% increase from the previous average price target of $3.60. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive OncoCyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $4.25 – Mike Matson Needham Raises Buy $4.25 $3.60 Mason Carrico Stephens & Co. Maintains Equal-Weight $4.00 – Bruce Jackson Benchmark Maintains Speculative Buy $5.00 – Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related …Full story available on Benzinga.com
181493
News
Related on Reddit
Related on X
Related on YouTube
Spotify’s Next Huge Growth Driver Will Shock You
Audiobooks aren’t just a side business for Spotify, they’re a future growth driver.
Continue Reading
Copied
Related Events
No related events associated to this feed.
Latest Feed
May 16, 2024
24 mins ago
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
SANTA ANA, Calif., May 16, 2024 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapeutics, today announced that Paul Y. Song, MD, Chairman and Chief Executive Officer of NKGen, will present highlights of the Company’s cryopreserved, autologous, non-genetically modified NK cell therapy product, SNK01, which has demonstrated enhanced cytotoxicity and activating receptor expression for the treatment of neurodegenerative diseases and solid tumors, at the 5th International Cell & Gene Therapy China Summit & Exhibition (CGCS) to be held in Nanjing, China, from May 22–24, 2024.
NKGN
181491
News
May 16, 2024
24 mins ago
LED Lighting and EV Charging Solutions Provider Orion Previews FY 2024 Results in Anticipation of its Singular Research Webinar Presentation Wed. May 22 at 3pm ET
LED Lighting and EV Charging Solutions Provider Orion Previews FY 2024 Results Ahead of its Singular Research Webinar Presentation, Wed. 5/22 at 3pm ET.
OESX
181492
News
May 16, 2024
26 mins ago
4 Analysts Assess OncoCyte: What You Need To Know
Analysts’ ratings for OncoCyte (NASDAQ:OCX) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 Analysts have set 12-month price targets for OncoCyte, revealing an average target of $4.38, a high estimate of $5.00, and a low estimate of $4.00. This upward trend is evident, with the current average reflecting a 21.67% increase from the previous average price target of $3.60. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive OncoCyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Maintains Buy $4.25 – Mike Matson Needham Raises Buy $4.25 $3.60 Mason Carrico Stephens & Co. Maintains Equal-Weight $4.00 – Bruce Jackson Benchmark Maintains Speculative Buy $5.00 – Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they ‘Maintain’, ‘Raise’ or ‘Lower’ their stance, it reflects their reaction to recent developments related …Full story available on Benzinga.com
OCX
181493
News
Related on Reddit
Related on X
Related on YouTube
Connect with your community
Introducing Audio Rooms: Engage in real-time discussions on community or news topics with fellow users. Each article or post can instantly create its exclusive audio room, facilitating conversations about subjects directly tied to the article or community post.
Audio Room Title:
Spotify’s Next Huge Growth Driver Will Shock You
Someone already created an audio of this feed.
Join the room
How it Works
Seeking Alpha
Bezinga
Market Rebellion
Motley Fool
And More!
Not a TradeZing PLUS Member?
Subscribe now for exclusive advantages and benefits!
How it Works
Seeking Alpha
Bezinga
Market Rebellion
Motley Fool
And More!
Not a TradeZing PLUS Member?
Subscribe now for exclusive advantages and benefits!
9 Comments
Most Voted
16 days ago
This could be a game-changer for their business model!
16 days ago
It’ll be fascinating to see how they integrate this into their platform and compete with other audiobook services.
16 days ago
That’s unexpected! I’m curious to see if they can leverage their existing user base to make this venture successful.
16 days ago
Pretty excited to see where this takes us!
16 days ago
Spotify’s really stepping up their game!
16 days ago
Can’t wait for my next road trip playlist to include not just tunes, but thrilling stories too!
15 days ago
Shocking revelation.
15 days ago
Next big driver.
15 days ago
Spotify’s growth surprise.